Strong fundamental, increasing profit margin (2016-2019), considerably low PE among pharmaceutical counters.
A clear up trend since 2009 and currently within a bullish channel from May'20 UTD, coupled with good signal from OBV, therefore a plausible TP of 4.0.
Superln is one of the rare company which showed +ve NPM for all quarters since 2015; strong fin. health and fat asset (NCAV, NNWC); and yet considered undervalued (PB<1), unlike supermx.
The TP and whether-or-not it can rise back to its peak (~RM3 @Aug'17) are still questionable because its segment was not in trending (i.e., gloves, med, ICT) atm.
Looking at the...
